查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1490315

ADC合約製造市場:產業趨勢與全球預測(-2035)-

ADC Contract Manufacturing Market : Industry Trends and Global Forecasts, till 2035 - Distribution by Stage of Development, Process Component, Target Indication, Antibody Isotype, Type of Payload, Type of Linker, and Key Geographical Regions
出版日期: | 出版商: Roots Analysis | 英文 510 Pages | 商品交期: 最快1-2個工作天內

價格
依開發階段,製程組件,適應症,抗體產生,抗體來源,抗體同種型,有效負載類型,連接子類型和主要地理區域

ADC合約製造市場規模預計到2024年將達到17.9億美元，並在2024-2035年預測期間以13%的複合年增長率擴張。

近年來，抗體藥物偶聯物（ADC）已成為治療多種癌症的強大治療方法，包括實體腫瘤和血液惡性腫瘤。這些複雜的化合物由與生物活性細胞毒劑化學綴合的抗體組成，從而提高了穩定性、標靶特異性、腫瘤選擇性和藥物動力學特性。這些特性刺激了廣泛的研究和開發，旨在將 ADC 療法推向市場。ADC 管線目前擁有超過 260 個候選藥物正在接受臨床評估，23 個 ADC 治療方案已獲得監管機構批准。精確靶向腫瘤細胞且脫靶毒性最小的 ADC 療法已取得成功，並在醫療保健領域中廣泛採用。

然而，ADC 的製造過程複雜且充滿課題，包括藥物/接頭副反應、毒性暴露、污染風險和放大難度。此外，它需要大量的專業知識和尖端技術，而且成本高昂。因此，ADC 開發公司通常選擇將製造外包給專業的 ADC 合約製造商。透過利用這些合約製造組織 (CMO) 的專業知識、能力和製造設施，ADC 療法開發商旨在簡化製造運營，同時降低成本。值得注意的是，參與 ADC 合約製造的 CMO 正在積極努力發展成為綜合解決方案提供商，以應對技術轉移和規模化課題。由於對 ADC 的需求不斷增加以及藥物開發公司對外包的偏好日益增加，預計 ADC 合約製造市場在短期內將顯著增長。

本報告調查了全球ADC 合約製造市場，並依開發階段、依工藝成分、依適應症、依抗體生成、依抗體來源、依抗體同種型、依有效負載類型和依連接體類型提供了市場概述。

目錄

第1章 前言

第2章 研究方法

第3章 經濟和其他專案特定考慮因素

第4章 執行摘要

第5章 簡介

第6章 ADC 合約製造商：市場狀況

第7章 公司簡介

  • 章節概述
  • MabPlex
  • Lonza
  • Abzena
  • GBI
  • CARBOGEN AMCIS
  • Millipore Sigma
  • WuXi Biologics
  • Catalent Pharma Solutions
  • Cerbios-Pharma
  • Formosa Laboratories
  • Sterling Pharma Solutions
  • Piramal Pharma Solutions
  • AbbVie Contract Manufacturing

第8章 企業競爭分析

第9章 ADC 合約製造商：近期擴張

第10章 ADC 合約製造商：夥伴關係與協作

第11章 自製與購買決策

第12章 價值鏈分析

第13章 ADC 製造：產能分析

第14章 ADC療法：市場概述

第15章 臨床試驗分析

  • 章節概述
  • 範圍和方法
  • 抗體藥物偶聯物：臨床試驗分析

第16章 合作夥伴候選人分析

第17章 ADC 療法：需求分析

第18章 區域能力分析

  • 章節概述
  • 假設和關鍵參數
  • 北美
  • 歐洲
  • 亞太及其他地區

第19章 吸引力與競爭力矩陣

第20章 ADC代工市場

第21章 ADC 合約製造市場，依發展階段劃分

第22章 ADC 合約製造市場（依製程組件）

第23章 ADC合約製造市場，依指標劃分

第24章 ADC合約製造市場，以抗體生成

第25章 ADC 合約製造市場（以抗體來源）

第26章 ADC合約製造市場，依抗體同種型劃分

第27章 ADC 合約製造市場（依有效負載類型）

第28章 ADC 合約製造市場，依連結器類型

第29章 ADC合約製造市場，依主要地區劃分

第30章 商業ADC合約製造市場

第31章 臨床ADC合約製造市場

第32章 市場影響分析：驅動因素、限制因素、機會、課題

第33章 結論

第34章 訪談紀錄

第35章 附錄一：表格數據

第36章 附錄二：公司與組織名單

Product Code: RA100365

ADC Contract Manufacturing Market (6th Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Stage of Development (Phase I, Phase II, Phase III and Commercial), Process Component (Antibody, HPAPI / Cytotoxic Payload, Conjugation / Linker and Fill / Finish), Target Indication (Solid Tumors, Hematological Tumors and Others), Antibody Generation (Second, Third, Fourth and Next), Antibody Origin (Humanized, Chimeric, Murine and Others), Antibody Isotype (IgG1, IgG4 and Others), Type of Payload (Auristatin, Camptothecin, DNA Topoisomerase I Inhibitor, Maytansinoid and Others), Type of Linker (Maleimide, SMCC, Tetrapeptide-based linker, Valine-citrulline and Others), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)

The ADC Contract Manufacturing Market is valued at USD 1.79 billion in 2024 growing at a CAGR of 13% during the forecast period 2024-2035.

In recent years, antibody drug conjugates (ADCs) have emerged as a powerful therapeutic approach for treating a broad spectrum of cancers, encompassing both solid tumors and hematological malignancies. These sophisticated compounds consist of an antibody chemically linked to biologically active cytotoxic agents, offering improved stability, target specificity, tumor selectivity, and pharmacokinetic properties. These attributes have spurred extensive research and development efforts aimed at advancing ADC therapies to market fruition. Presently, the ADC pipeline boasts over 260 candidates undergoing clinical evaluation, alongside 23 ADC therapeutic programs already sanctioned by regulatory bodies. The promise of such therapies in precisely targeting tumor cells while minimizing off-target toxicities has propelled their success and widespread adoption within the healthcare sector.

Nevertheless, the manufacturing process for ADCs is intricately complex, fraught with various challenges such as drug/linker side reactions, toxicity exposure, contamination risks, and scale-up difficulties. Additionally, it demands substantial expertise and cutting-edge technologies, incurring significant costs. Consequently, ADC developers often opt to outsource manufacturing operations to specialized ADC contract manufacturers. By leveraging the expertise, capabilities, and production facilities of these contract manufacturing organizations (CMOs), ADC therapy developers aim to streamline manufacturing operations while reducing costs. Notably, CMOs involved in ADC contract manufacturing are actively striving to evolve into comprehensive solution providers, addressing challenges related to technology transfer and scale-up. With the escalating demand for ADCs and the growing inclination toward outsourcing among drug developers, the ADC contract manufacturing market is poised for substantial growth in the foreseeable future.

Key Market Segments

Stage of Development

  • Phase I
  • Phase II
  • Phase III
  • Commercial

Process Component

  • Antibody
  • HPAPI / Cytotoxic Payload
  • Conjugation / Linker
  • Fill / Finish

Target Indication

  • Solid Tumors
  • Hematological Tumors
  • Others

Antibody Generation

  • Second Generation
  • Third Generation
  • Fourth Generation
  • Next Generation

Antibody Origin

  • Humanized
  • Chimeric
  • Murine
  • Others

Antibody Isotype

  • IgG1
  • IgG4
  • Others

Type of Payload

  • Auristatin
  • Camptothecin
  • DNA Topoisomerase I Inhibitor
  • Maytansinoid
  • Others

Type of Linker

  • Maleimide

SMCC

  • Tetrapeptide-based linker
  • Valine-citrulline
  • Others

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific and Rest of the World

Research Coverage:

  • Insightful overview on the essential components of ADC therapeutics, the challenges associated with manufacturing of such therapies along with information on the rising trend of contract manufacturing in this segment of biopharmaceutical industry.
  • An in-depth analysis of the comprehensive market landscape for ADC contract manufacturers involves evaluating various pertinent factors. These include the establishment year, company size denoted by the number of employees, headquarters location, and the range of ADC manufacturing services provided, encompassing antibody manufacturing, HPAPI and payload synthesis, linker manufacturing, conjugation, and fill/finish services. Additionally, consideration is given to the types of additional services offered, such as proof-of-concept studies, process development and scale-up, and analytical development. The scale of operation, categorized into preclinical, clinical, and commercial phases, is also a crucial aspect. Moreover, the geographic location of manufacturing facilities plays a significant role in assessing the overall landscape of ADC contract manufacturers.
  • Comprehensive competitiveness analysis of ADC contract manufacturers, based on manufacturing strength (in terms of scale of operation and number of ADC manufacturing facilities), service strength (in terms of number of ADC services offered, number of additional services offered and location of ADC manufacturing facilities) and supplier strength (in terms of employee count and years of experience in this field).
  • Elaborate profiles of ADC contract manufacturers (shortlisted on the basis of competitiveness analysis). Each profile provides a brief overview of the company, its financial information (if available), manufacturing services portfolio (specific to antibody drug conjugates), location of production facilities, and an insightful recent development and future outlook.
  • A detailed analysis of the various expansion initiatives undertaken by ADC contract manufacturers, during the period 2019-2023, along with information on several relevant parameters, such as year of expansion, type of expansion, purpose of expansion (manufacturing, analytical / development and fill / finish), scale of operation (preclinical, clinical and commercial), location of expanded facility, type of facility and most active players (based on number of expansion initiatives).
  • An analysis of the recent partnerships inked between various ADC contract manufacturers, since 2019, based on several parameters, such as year of partnership, type of partnership (acquisitions, joint ventures, licensing agreements, manufacturing agreements, mergers, product development agreements, product development and manufacturing agreements, research agreements, technology integration agreements and others), purpose of agreement, scale of operation and most active players (in terms of number of partnerships). This section also highlights the regional distribution of partnership activity in this market.
  • A qualitative analysis highlighting the various factors that need to be considered by ADC developers, while deciding whether to manufacture their respective products in-house or outsource the manufacturing operation to contract service providers.
  • A detailed discussion on various steps (antibody manufacturing, payload manufacturing, linker manufacturing, conjugation and fill / finish) involved in the manufacturing of ADCs, along with information on the cost requirements across each stage.
  • An estimate of the overall ADC manufacturing / bioconjugation capacity (in kilograms) of ADC contract manufacturers based on information provided by various stakeholders in the public domain. The analysis highlights the distribution of global capacity by company size (small, mid-sized and large), key geographical regions (North America, Europe and Asia-Pacific) and key players (in terms of highest bioconjugation capacity).
  • An overview of the current market landscape of ADCs, along with detailed analysis of the ADCs pipeline, based on several relevant parameters, such as status of development, target disease indication, therapeutic area, line of treatment, dosing frequency, type of therapy, target antigen, antibody isotype, payload / cytotoxin / warhead, type of payload and type of linker.
  • An in-depth analysis of completed and ongoing clinical studies of various antibody drug conjugates, based on several relevant parameters, such as trial registration year, trial status, trial phase, enrolled patient population, type of sponsor / collaborator, target population, study design, most active industry players, and non-industry players (in terms of number of trials) and key geographical regions.
  • An in-depth analysis of over 140 ADC therapy developers that are likely to partner with ADC contract manufacturers, based on several relevant parameters, such as developer strength (in terms of company size and its experience), pipeline maturity (in terms of number of drugs in pipeline, their stage of development and type of target indication) and manufacturing capabilities.
  • An informed estimate of the annual commercial and clinical demand for ADC therapeutics (in kilograms) based on, based on relevant parameters, such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.
  • A detailed regional capability assessment framework comparing the key geographies, based on a number of parameters, including the number of ADC contract manufacturers, number of ADC manufacturing facilities, number of facility expansions, installed ADC bioconjugation capacity, number of registered clinical trials and demand for ADCs in that particular geographical region.
  • A detailed assessment of the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments, plotted on a 2X2 matrix.
  • A detailed ADC contract manufacturing market forecast analysis in order to estimate the existing market size and future opportunity for ADC contract manufacturers over the next 12 years. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market size during the forecast period 2024-2035.
  • Detailed projections of the current and future opportunity within the ADC contract manufacturing market across different stages of development, such as phase I, phase II, phase III and commercial.
  • Detailed projections of the current and future opportunity within antibody drug conjugates contract manufacturing market across different process components, such as antibody, HPAPI / cytotoxic payload, conjugation / linker and fill / finish.
  • Detailed projections of the current and future opportunity within the ADC contract manufacturing industry across different target indications, such as solid tumors, hematological tumors and others.
  • Detailed projections of the current and future opportunity within the market across different antibody generations, such as second, third, fourth and next generation.
  • Detailed projections of the current and future opportunity within the ADC contract manufacturing market across different antibody origins, such as humanized, chimeric, murine and others.
  • Detailed projections of the current and future opportunity within the antibody drug conjugates contract manufacturing market across different antibody isotypes, such as IgG1, IgG4 and others.
  • Detailed projections of the current and future opportunity within the ADC contract manufacturing market across different types of payloads, such as auristatin, camptothecin, DNA topoisomerase I inhibitor, maytansinoid and others.
  • Detailed projections of the current and future opportunity within the market across different types of linkers, such as Maleimide, SMCC, tetrapeptide-based linker, valine-citrulline and others.
  • Detailed projections of the current and future opportunity within the ADC contract manufacturing industry across key geographical regions, including North America, Europe, Asia-Pacific and rest of the world.
  • Detailed projections of the current and future opportunity within the commercial ADC contract manufacturing market, based on several relevant parameters such as type of component, target indications, type of generation, type of antibody origin, type of antibody isotype, type of payload, type of linker and key geographical regions.
  • Detailed projections of the current and future opportunity within the clinical ADC contract manufacturing market, based on several relevant parameters such as phase of development, type of component, target indications, type of antibody origin, type of antibody isotype, type of payload, type of linker and key geographical regions.
  • An in-depth analysis of the factors that can impact on the growth of ADC contract manufacturing market. It also features identification of key drivers, potential restraints, emerging opportunities, and existing challenges.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the ADC Contract Manufacturing Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

  • AbbVie Contract Manufacturing
  • Abzena

CARBOGEN AMCIS

  • Catalent Pharma Solutions
  • Cerbios-Pharma
  • Formosa Laboratories

GBI

  • Lonza
  • MabPlex
  • Millipore Sigma
  • Piramal Pharma Solutions
  • Sterling Pharma Solutions
  • WuXi Biologics

TABLE OF CONTENTS

Table Of Contents

1. PREFACE

  • 1.1. ADC Contract Manufacturers: Market Overview
  • 1.2. Market Share Insights
  • 1.3. Market Segmentation Overview
  • 1.4. Key Market Insights
  • 1.5. Report Coverage
  • 1.6. Key Questions Answered
  • 1.7. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Key Components of ADCs
    • 5.2.1. Antibody
    • 5.2.2. Cytotoxin (Payloads)
    • 5.2.3. Linker
  • 5.3. ADC Manufacturing
    • 5.3.1. Key Steps
    • 5.3.2. Technical Challenges
    • 5.3.3. Need for Outsourcing
  • 5.4. Challenges Associated with Supply Chain and Method Transfer
    • 5.4.1. Growing Demand for One-Stop Shops and Integrated Service Providers
  • 5.5. Selecting a CMO Partner
  • 5.6. Future Perspective

6. ADC CONTRACT MANUFACTURERS: MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. ADC Contract Manufacturers: Overall Market Landscape
    • 6.2.1. Analysis by Year of Establishment
    • 6.2.2. Analysis by Company Size
    • 6.2.3. Analysis by Location of Headquarters
    • 6.2.4. Analysis by Type of ADC Manufacturing Service Offered
    • 6.2.5. Analysis by Type of Additional Service Offered
    • 6.2.6. Analysis by Scale of Operation
    • 6.2.7. Analysis by Location of Manufacturing Facilities

7. COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. MabPlex
    • 7.2.1. Company Overview
    • 7.2.2. ADC Related Services
    • 7.2.3. Manufacturing Facilities
    • 7.2.4. Recent Developments and Future Outlook
  • 7.3. Lonza
    • 7.3.1. Company Overview
    • 7.3.2. Financial Information
    • 7.3.3. ADC Related Services
    • 7.3.4. Manufacturing Facilities
    • 7.3.5. Recent Developments and Future Outlook
  • 7.4. Abzena
    • 7.4.1. Company Overview
    • 7.4.2. ADC Related Services
    • 7.4.3. Manufacturing Facilities
    • 7.4.4. Recent Developments and Future Outlook
  • 7.5. GBI
    • 7.5.1. Company Overview
    • 7.5.2. ADC Related Services
    • 7.5.3. Manufacturing Facilities
    • 7.5.4. Recent Developments and Future Outlook
  • 7.6. CARBOGEN AMCIS
    • 7.6.1. Company Overview
    • 7.6.2. ADC Related Services
    • 7.6.3. Manufacturing Facilities
    • 7.6.4. Recent Developments and Future Outlook
  • 7.7. Millipore Sigma
    • 7.7.1. Company Overview
    • 7.7.2. ADC Related Offerings
    • 7.7.3. Manufacturing Facilities
    • 7.7.4. Recent Developments and Future Outlook
  • 7.8. WuXi Biologics
    • 7.8.1. Company Overview
    • 7.8.2. Financial Information
    • 7.8.3. ADC Related Services
    • 7.8.4. Manufacturing Facilities
    • 7.8.5. Recent Developments and Future Outlook
  • 7.9. Catalent Pharma Solutions
    • 7.9.1. Company Overview
    • 7.9.2. Financial Information
    • 7.9.3. ADC Related Services
    • 7.9.4. Manufacturing Facilities
    • 7.9.5. Recent Developments and Future Outlook
  • 7.10. Cerbios-Pharma
    • 7.10.1. Company Overview
    • 7.10.2. ADC Related Services
    • 7.10.3. Manufacturing Facilities
    • 7.10.4. Recent Developments and Future Outlook
  • 7.11. Formosa Laboratories
    • 7.11.1. Company Overview
    • 7.11.2. ADC Related Services
    • 7.11.3. Manufacturing Facilities
    • 7.11.4. Recent Developments and Future Outlook
  • 7.12. Sterling Pharma Solutions
    • 7.12.1. Company Overview
    • 7.12.2. ADC Related Services
    • 7.12.3. Manufacturing Facilities
    • 7.12.4. Recent Developments and Future Outlook
  • 7.13. Piramal Pharma Solutions
    • 7.13.1. Company Overview
    • 7.13.2. ADC Related Services
    • 7.13.3. Manufacturing Facilities
    • 7.13.4. Recent Developments and Future Outlook
  • 7.14. AbbVie Contract Manufacturing
    • 7.14.1. Company Overview
    • 7.14.2. ADC Related Services
    • 7.14.3. Manufacturing Facilities
    • 7.14.4. Recent Developments and Future Outlook

8. COMPANY COMPETITIVENESS ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Assumptions and Key Parameters
  • 8.3. Methodology
  • 8.4. ADC Contract Manufacturers: Company Competitiveness Analysis
    • 8.4.1. ADC Contract Manufacturers based in North America (Peer Group I)
    • 8.4.2. ADC Contract Manufacturers based in Europe (Peer Group II)
    • 8.4.3. ADC Contract Manufacturers based in Asia-Pacific (Peer Group III)
  • 8.5. Capability Benchmarking of Top ADC Contract Manufacturers

9. ADC CONTRACT MANUFACTURERS: RECENT EXPANSIONS

  • 9.1. Chapter Overview
  • 9.2. ADC Contract Manufacturers: Recent Expansions
    • 9.2.1. Analysis by Year of Expansion
    • 9.2.2. Analysis by Type of Expansion
    • 9.2.3. Analysis by Purpose of Expansion
    • 9.2.4. Analysis by Scale of Operation
    • 9.2.5. Analysis by Location of Expanded Facility
    • 9.2.6. Most Active Players: Analysis by Number of Expansions

10. ADC CONTRACT MANUFACTURERS: PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Chapter Overview
  • 10.2. Partnership Models
  • 10.3. ADC Contract Manufacturers: Partnerships and Collaborations
    • 10.3.1. Analysis by Year of Partnership
    • 10.3.2. Analysis by Type of Partnership
    • 10.3.3. Analysis by Purpose of Partnership
    • 10.3.4. Analysis by Scale of Operation
    • 10.3.5. Most Active Players: Analysis by Number of Partnerships
    • 10.3.6. Analysis by Geography
      • 10.3.6.1. Intercontinental and Intracontinental Agreements
      • 10.3.6.2. Local and International Agreements

11. MAKE VERSUS BUY DECISION MAKING

  • 11.1. Chapter Overview
  • 11.2. Assumptions and Key Parameters
    • 11.2.1. Scenario 1
    • 11.2.2. Scenario 2
    • 11.2.3. Scenario 3
    • 11.2.4. Scenario 4
  • 11.3. Concluding Remarks

12. VALUE CHAIN ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. ADC Development Value Chain
  • 12.3. Cost Distribution across the Value Chain
    • 12.3.1. Cost Associated with Antibody Manufacturing
    • 12.3.2. Cost Associated with Payload and Linker Manufacturing
    • 12.3.3. Cost Associated with Conjugation
    • 12.3.4. Cost Associated with Fill / Finish

13. ADC MANUFACTURING: CAPACITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Key Assumptions and Methodology
  • 13.3. ADC Manufacturing: Global Installed Capacity
    • 13.3.1. Analysis by Company Size
    • 13.3.2. Analysis by Location of Headquarters
    • 13.3.3. Analysis by Location of Manufacturing Facilities
      • 13.3.3.1 Analysis by Region
      • 13.3.3.2. Analysis by Country
    • 13.3.4. Analysis by Key Players

14. ADC THERAPEUTICS: MARKET OVERVIEW

  • 14.1. Chapter Overview
  • 14.2. Antibody Drug Conjugates: Therapies Pipeline
    • 14.2.1. Analysis by Status of Development
    • 14.2.2. Analysis by Target Disease Indication
    • 14.2.3. Analysis by Therapeutic Area
    • 14.2.4. Analysis by Line of Treatment
    • 14.2.5. Analysis by Dosing Frequency
    • 14.2.6. Analysis by Type of Therapy
    • 14.2.7. Analysis by Target Antigen
    • 14.2.8. Analysis by Antibody Isotype
    • 14.2.9. Analysis by Payload / Cytotoxin / Warhead
    • 14.2.10. Analysis by Type of Payload
    • 14.2.11. Analysis by Linker
    • 14.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
  • 14.3. Antibody Drug Conjugates: Therapies to Watch
  • 14.4. Concluding Remarks

15. CLINICAL TRIAL ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Scope and Methodology
  • 15.3. Antibody Drug Conjugates: Clinical Trial Analysis
    • 15.3.1. Analysis by Trial Registration Year
    • 15.3.2. Analysis by Trial Status
    • 15.3.3. Analysis of Enrolled Patient Population by Trial Status
    • 15.3.4. Analysis by Trial Registration Year and Trial Status
    • 15.3.5. Analysis of Enrolled Patient Population by Trial Registration Year
    • 15.3.6. Analysis by Trial Phase
    • 15.3.7. Analysis of Enrolled Patient Population by Trial Phase
    • 15.3.8. Analysis by Type of Sponsor / Collaborator
    • 15.3.9. Analysis by Target Population
    • 15.3.10. Analysis by Study Design
    • 15.3.11. Most Active Industry Players: Analysis by Number of Trials
    • 15.3.12. Most Active Non-Industry Players: Analysis by Number of Trials
    • 15.3.13. Analysis of Clinical Trials by Geography
    • 15.3.14. Analysis of Enrolled Patient Population by Geography

16. LIKELY PARTNER ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Scoring Criteria and Key Assumptions
  • 16.3. Scope and Methodology
  • 16.4. Potential Strategic Partners based in North America
    • 16.4.1. Most Likely Partners
    • 16.4.2. Likely Partners
    • 16.4.3. Least Likely Partners
  • 16.5. Potential Strategic Partners based in Europe
    • 16.5.1. Most Likely Partners
    • 16.5.2. Likely Partners
    • 16.5.3. Least Likely Partners
  • 16.6. Potential Strategic Partners based in Asia-Pacific and Rest of the World
    • 16.6.1. Most Likely Partners
    • 16.6.2. Likely Partners
    • 16.6.3. Least Likely Partners

17. ADC THERAPEUTICS: DEMAND ANALYSIS

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. ADC Therapeutics: Global Annual Demand
    • 17.3.1. ADC Therapeutics: Annual Commercial Demand
      • 17.3.1.1. Analysis by Target Indication
      • 17.3.1.2. Analysis by Antibody Origin
      • 17.3.1.3. Analysis by Antibody Isotype
      • 17.3.1.4. Analysis by Type of Payload
      • 17.3.1.5. Analysis by Type of Linker
      • 17.3.1.6 Analysis by Key Geographical Regions
    • 17.3.2. ADC Therapeutics: Annual Clinical Demand
      • 17.3.2.1. Analysis by Phase of Development
      • 17.3.2.2. Analysis by Target Indication
      • 17.3.2.3. Analysis by Antibody Origin
      • 17.3.2.4. Analysis by Antibody Isotype
      • 17.3.2.5. Analysis by Type of Payload
      • 17.3.2.6. Analysis by Type of Linker
      • 17.3.2.7. Analysis by Key Geographical Regions

18. REGIONAL CAPABILITY ANALYSIS

  • 18.1. Chapter Overview
  • 18.2. Assumptions and Key Parameters
  • 18.3. ADC Contract Manufacturing Capabilities in North America
  • 18.4. ADC Contract Manufacturing Capabilities in Europe
  • 18.5. ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World

19. ATTRACTIVENESS COMPETETIVENESS MATRIX

  • 19.1. Chapter Overview
  • 19.2. AC Matrix: Overview
    • 19.2.1. Strong Business Segments
    • 19.2.2. Average Business Segments
    • 19.2.3. Weak Business Segments
  • 19.3. AC Matrix: Analytical Methodology
  • 19.4. AC Matrix: Overall ADC Contract Manufacturing Market Scenario
    • 19.4.1. AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
    • 19.4.2. AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions

20. ADC CONTRACT MANUFACTURING MARKET

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Global ADC Therapeutics Market, Historical Trends and Forecasted Estimates, till 2035
  • 20.4. Global ADC Contract Manufacturing Market, Historical Trends and Forecasted Estimates, till 2035
    • 20.4.1. Scenario Analysis
  • 20.5. Key Market Segmentations

21. ADC CONTRACT MANUFACTURING MARKET, BY STAGE OF DEVELOPMENT

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. ADC Contract Manufacturing Market: Distribution by Stage of Development, 2023, 2028 and 2035
    • 21.3.1. Phase I: Forecasted Estimates, till 2035
    • 21.3.2. Phase II: Forecasted Estimates, till 2035
    • 21.3.3. Phase III: Forecasted Estimates, till 2035
    • 21.3.4. Commercial: Forecasted Estimates, till 2035
  • 21.4. Data Triangulation and Validation

22. ADC CONTRACT MANUFACTURING MARKET, BY PROCESS COMPONENT

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. ADC Contract Manufacturing Market: Distribution by Process Component, 2023, 2028 and 2035
    • 22.3.1. Antibody: Forecasted Estimates, till 2035
    • 22.3.2. HPAPI / Cytotoxic Payload: Forecasted Estimates, till 2035
    • 22.3.3. Conjugation / Linker: Forecasted Estimates, till 2035
    • 22.3.4. Fill / Finish: Forecasted Estimates, till 2035
  • 22.4. Data Triangulation and Validation

23. ADC CONTRACT MANUFACTURING MARKET, BY TARGET INDICATION

  • 23.1. Chapter Overview
  • 23.2. Key Assumptions and Methodology
  • 23.3. ADC Contract Manufacturing Market: Distribution by Target Indication, 2023, 2028 and 2035
    • 23.3.1. Solid Tumors: Forecasted Estimates, till 2035
    • 23.3.2. Hematological Tumors: Forecasted Estimates, till 2035
    • 23.3.3. Others: Forecasted Estimates, till 2035
  • 23.4. Data Triangulation and Validation

24. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY GENERATION

  • 24.1. Chapter Overview
  • 24.2. Key Assumptions and Methodology
  • 24.3. ADC Contract Manufacturing Market: Distribution by Antibody Generation, 2023, 2028 and 2035
    • 24.3.1. Second Generation: Forecasted Estimates, till 2035
    • 24.3.2. Third Generation: Forecasted Estimates, till 2035
    • 24.3.3. Fourth Generation: Forecasted Estimates, till 2035
    • 24.3.4. Next Generation: Forecasted Estimates, till 2035
  • 24.4. Data Triangulation and Validation

25. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ORIGIN

  • 25.1. Chapter Overview
  • 25.2. Key Assumptions and Methodology
  • 25.3. ADC Contract Manufacturing Market: Distribution by Antibody Origin, 2023, 2028 and 2035
    • 25.3.1. Human Origin: Forecasted Estimates, till 2035
    • 25.3.2. Chimeric Origin: Forecasted Estimates, till 2035
    • 25.3.3. Murine Origin: Forecasted Estimates, till 2035
    • 25.3.4. Others: Forecasted Estimates, till 2035
  • 25.4. Data Triangulation and Validation

26. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ISOTYPE

  • 26.1. Chapter Overview
  • 26.2. Key Assumptions and Methodology
  • 26.3. ADC Contract Manufacturing Market: Distribution by Antibody Isotype, 2023, 2029 and 2035
    • 26.3.1. IgG1: Forecasted Estimates, till 2035
    • 26.3.2. IgG4: Forecasted Estimates, till 2035
    • 26.3.3. Others: Forecasted Estimates, till 2035
  • 26.4. Data Triangulation and Validation

27. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF PAYLOAD

  • 27.1. Chapter Overview
  • 27.2. Key Assumptions and Methodology
  • 27.3. ADC Contract Manufacturing Market: Distribution by Type of Payload, 2023, 2029 and 2035
    • 27.3.1. Camptothecin: Forecasted Estimates, till 2035
    • 27.3.2. Maytansinoid: Forecasted Estimates, till 2035
    • 27.3.3. Auristatin: Forecasted Estimates, till 2035
    • 27.3.4. DNA topoisomerase I inhibitor: Forecasted Estimates, till 2035
    • 27.3.5. Others: Forecasted Estimates, till 2035
  • 27.4. Data Triangulation and Validation

28. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF LINKER

  • 28.1. Chapter Overview
  • 28.2. Key Assumptions and Methodology
  • 28.3. ADC Contract Manufacturing Market: Distribution by Type of Linker, 2023, 2029 and 2035
    • 28.3.1. Maleimide: Forecasted Estimates, till 2035
    • 28.3.2. SMCC: Forecasted Estimates, till 2035
    • 28.3.3. Tetrapeptide-based linker: Forecasted Estimates, till 2035
    • 28.3.4. Valine-citrulline: Forecasted Estimates, till 2035
    • 28.3.5. Others: Forecasted Estimates, till 2035
  • 28.4. Data Triangulation and Validation

29. ADC CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 29.1. Chapter Overview
  • 29.2. Key Assumptions and Methodology
  • 29.3. ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023, 2029 and 2035
    • 29.3.1. North America: Forecasted Estimates, till 2035
    • 29.3.2. Europe: Forecasted Estimates, till 2035
    • 29.3.3. Asia-Pacific and Rest of the World: Forecasted Estimates, till 2035
  • 29.4. Data Triangulation and Validation

30. COMMERCIAL ADC CONTRACT MANUFACTURING MARKET

  • 30.1. Chapter Overview
  • 30.2. Key Assumptions and Methodology
  • 30.3. Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035
    • 30.3.1. Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035
    • 30.3.2. Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035
    • 30.3.3. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Generation, Forecasted Estimates, till 2035
    • 30.3.4. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035
    • 30.3.5. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035
    • 30.3.6. Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035
    • 30.3.7. Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035
    • 30.3.8. Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035
  • 30.4. Data Triangulation and Validation

31. CLINICAL ADC CONTRACT MANUFACTURING MARKET

  • 31.1. Chapter Overview
  • 31.2. Key Assumptions and Methodology
  • 31.3. Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035
    • 31.3.1. Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035
    • 31.3.2. Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035
    • 31.3.3. Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035
    • 31.3.4. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035
    • 31.3.5. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035
    • 31.3.6. Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035
    • 31.3.7. Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035
    • 31.3.8. Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035
  • 31.4. Data Triangulation and Validation

32. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 32.1. Chapter Overview
  • 32.2. Market Drivers
  • 32.3. Market Restraints
  • 32.4. Market Opportunities
  • 32.5. Market Challenges
  • 32.6. Conclusion

33. CONCLUDING REMARKS

34. INTERVIEW TRANSCRIPTS

35. APPENDIX I: TABULATED DATA

36. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 5.1 Common Cytotoxins used for the Production of ADCs
  • Table 5.2 Safebridge Categorization / OEL Bands for Highly Potent / Cytotoxic Compounds
  • Table 6.1 ADC Contract Manufacturers: Information on Year of Establishment, Company Size, Location of Headquarters and Type of Manufacturer
  • Table 6.2 ADC Contract Manufacturers: Information on Type of ADC Manufacturing Service Offered
  • Table 6.3 ADC Contract Manufacturers: Information on Type of Additional Service Offered and Scale of Operation
  • Table 6.4 ADC Contract Manufacturers: Information on Location of Manufacturing Facilities and Type of ADC Manufacturing Service Offered
  • Table 7.1 List of Companies Profiled
  • Table 7.2 MabPlex: Company Overview
  • Table 7.3 MabPlex: ADC Related Services
  • Table 7.4 MabPlex: Information on Manufacturing Facilities
  • Table 7.5 Lonza: Company Overview
  • Table 7.6 Lonza: ADC Related Services
  • Table 7.7 Lonza: Information on Manufacturing Facilities
  • Table 7.8 Lonza: Recent Developments and Future Outlook
  • Table 7.9 Abzena: Company Overview
  • Table 7.10 Abzena: ADC Related Services
  • Table 7.11 Abzena: Information on Manufacturing Facilities
  • Table 7.12 Abzena: Recent Developments and Future Outlook
  • Table 7.13 GBI: Company Overview
  • Table 7.14 GBI: ADC Related Services
  • Table 7.15 GBI: Information on Manufacturing Facilities
  • Table 7.16 CARBOGEN AMCIS: Company Overview
  • Table 7.17 CARBOGEN AMCIS: ADC Related Services
  • Table 7.18 CARBOGEN AMCIS: Information on Manufacturing Facilities
  • Table 7.19 CARBOGEN AMCIS: Recent Developments and Future Outlook
  • Table 7.20 Millipore Sigma: Company Overview
  • Table 7.21 Millipore Sigma: ADC Related Services
  • Table 7.22 Millipore Sigma: Information on Manufacturing Facilities
  • Table 7.23 WuXi Biologics: Company Overview
  • Table 7.24 WuXi Biologics: ADC Related Services
  • Table 7.25 WuXi Biologics: Information on Manufacturing Facilities
  • Table 7.26 WuXi Biologics: Recent Developments and Future Outlook
  • Table 7.27 Catalent Pharma Solutions: Company Overview
  • Table 7.28 Catalent Pharma Solutions: ADC Related Services
  • Table 7.29 Catalent Pharma Solutions: Information on Manufacturing Facilities
  • Table 7.30 Catalent Pharma Solutions: Recent Developments and Future Outlook
  • Table 7.31 Cerbios-Pharma: Company Overview
  • Table 7.32 Cerbios-Pharma: ADC Related Services
  • Table 7.33 Cerbios-Pharma: Information on Manufacturing Facilities
  • Table 7.34 Cerbios-Pharma: Recent Developments and Future Outlook
  • Table 7.35 Formosa Laboratories: Company Overview
  • Table 7.36 Formosa Laboratories: ADC Related Services
  • Table 7.37 Formosa Laboratories: Information on Manufacturing Facilities
  • Table 7.38 Sterling Pharma Solutions: Company Overview
  • Table 7.39 Sterling Pharma Solutions: ADC Related Services
  • Table 7.40 Sterling Pharma Solutions: Information on Manufacturing Facilities
  • Table 7.41 Sterling Pharma Solutions: Recent Developments and Future Outlook
  • Table 7.42 Piramal Pharma Solutions: Company Overview
  • Table 7.43 Piramal Pharma Solutions: ADC Related Services
  • Table 7.44 Piramal Pharma Solutions: Information on Manufacturing Facilities
  • Table 7.45 Piramal Pharma Solutions: Recent Developments and Future Outlook
  • Table 7.46 AbbVie Contract Manufacturing: Company Overview
  • Table 7.47 AbbVie Contract Manufacturing: ADC Related Services
  • Table 7.48 AbbVie Contract Manufacturing: Information on Manufacturing Facilities
  • Table 9.1 ADC Contract Manufacturers: Information on Month and Year of Expansion, Type of Expansion, Purpose of Expansion and Scale of Operation, 2019-2023
  • Table 9.2 ADC Contract Manufacturers: Information on Location of Expanded Facility and Type of Facility
  • Table 10.1 ADC Contract Manufacturers: Information on Year of Partnership, Type of Partnership, Purpose of Partnership and Scale of Operation, 2019-2023
  • Table 10.2 ADC Contract Manufacturers: Information on Type of Agreement (Country and Continent)
  • Table 12.1 ADC Components: Information on Cost of Cytotoxins
  • Table 12.2 ADC Components: Information on Cost of Linkers
  • Table 13.1 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Yield)
  • Table 13.2 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Average Capacity)
  • Table 13.3 Global Installed ADC Manufacturing Capacity: Information on Total Capacity based on Company Size
  • Table 14.1 Antibody Drug Conjugates: Information on Drug Candidates, Developers, Status of Development, Target Disease Indication and Therapeutic Area
  • Table 14.2 Antibody Drug Conjugates to Watch: Information on Drug Candidates, Developer, Status of Development, Target Disease Indication and Therapeutic Area
  • Table 16.1 Most Likely Partners based in North America
  • Table 16.2 Likely Partners based in North America
  • Table 16.3 Least Likely Partners based in North America
  • Table 16.4 Most Likely Partners based in Europe
  • Table 16.5 Likely Partners based in Europe
  • Table 16.6 Least Likely Partners based in Europe
  • Table 16.7 Most Likely Partners based in Asia-Pacific and Rest of the World
  • Table 16.8 Likely Partners based in Asia-Pacific and Rest of the World
  • Table 16.9 Least Likely Partners based in Asia-Pacific and Rest of the World
  • Table 17.1 List of Late-Stage ADCs
  • Table 34.1 BSP Pharmaceuticals: Key Highlights
  • Table 34.2 Oxford BioTherapeutics: Key Highlights
  • Table 34.3 Abzena: Key Highlights
  • Table 34.4 Syndivia: Key Highlights
  • Table 34.5 Cerbios-Pharma: Key Highlights
  • Table 34.6 NBE-Therapeutics: Key Highlights
  • Table 34.7 Eisai: Key Highlights
  • Table 34.8 Synaffix: Key Highlights
  • Table 34.9 Pierre Fabre: Key Highlights
  • Table 34.10 Goodwin Biotechnology: Key Highlights
  • Table 34.11 Cerbios-Pharma: Key Highlights
  • Table 34.12 Catalent Pharma Solutions: Key Highlights
  • Table 34.13 Lonza: Key Highlights
  • Table 34.14 Piramal Pharma Solutions: Key Highlights
  • Table 34.15 Ajinomoto Bio-Pharma Services: Key Highlights
  • Table 35.1 ADC Contract Manufacturers: Distribution by Year of Establishment
  • Table 35.2 ADC Contract Manufacturers: Distribution by Company Size
  • Table 35.3 ADC Contract Manufacturers: Distribution by Location of Headquarters (Region)
  • Table 35.4 ADC Contract Manufacturers: Distribution by Location of Headquarters (Country)
  • Table 35.5 ADC Contract Manufacturers: Distribution by Company Size and Location of Headquarters
  • Table 35.6 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered
  • Table 35.7 ADC Contract Manufacturers: Distribution by Location of Headquarters and ADC Manufacturing Service Offered
  • Table 35.8 ADC Contract Manufacturers: Distribution by Type of Additional Service Offered
  • Table 35.9 ADC Contract Manufacturers: Distribution by Scale of Operation
  • Table 35.10 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered and Scale of Operation
  • Table 35.11 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities and Type of ADC Manufacturing Service Offered
  • Table 35.12 Lonza: Annual Revenues, FY 2019-H1 FY 2023 (CHF Billion)
  • Table 35.13 WuXi Biologics: Annual Revenues, FY 2019-H1 FY 2023 (RMB Billion)
  • Table 35.14 Catalent Pharma Solutions: Annual Revenues, FY 2019 - FY 2023 (USD Billion)
  • Table 35.15 Recent Expansions: Cumulative Year-wise Trend, 2013-2023
  • Table 35.16 Recent Expansions: Distribution by Type of Expansion
  • Table 35.17 Recent Expansions: Distribution by Purpose of Expansion
  • Table 35.18 Recent Expansions: Distribution by Year of Expansion and Purpose of Expansion
  • Table 35.19 Recent Expansions: Distribution by Scale of Operation
  • Table 35.20 Recent Expansions: Distribution by Location of Expanded Facility
  • Table 35.21 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
  • Table 35.22 Most Active Players: Distribution by Number of Expansions
  • Table 35.23 Partnerships and Collaborations: Cumulative Year-wise Trend, 2012-2023
  • Table 35.24 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 35.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 35.26 Partnerships and Collaborations: Distribution by Purpose of Partnership
  • Table 35.27 Partnerships and Collaborations: Distribution by Scale of Operation
  • Table 35.28 Most Active Players: Distribution by Number of Partnership Instances
  • Table 35.29 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
  • Table 35.30 Partnerships and Collaborations: Distribution by Local and International Agreements
  • Table 35.31 Global Installed ADC Manufacturing Capacity: Distribution by Company Size
  • Table 35.32 Global Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
  • Table 35.33 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Region)
  • Table 35.34 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Country)
  • Table 35.35 Global Installed ADC Manufacturing Capacity: Distribution by Key Players
  • Table 35.36 Antibody Drug Conjugates: Distribution by Status of Development
  • Table 35.37 Antibody Drug Conjugates: Distribution by Target Disease Indication
  • Table 35.38 Antibody Drug Conjugates: Distribution by Therapeutic Area
  • Table 35.39 Antibody Drug Conjugates: Distribution by Line of Treatment
  • Table 35.40 Antibody Drug Conjugates: Distribution by Dosing Frequency
  • Table 35.41 Antibody Drug Conjugates: Distribution by Type of Therapy
  • Table 35.42 Antibody Drug Conjugates: Distribution by Target Antigen
  • Table 35.43 Antibody Drug Conjugates: Distribution by Antibody Isotype
  • Table 35.44 Antibody Drug Conjugates: Distribution by Payload / Cytotoxin / Warhead
  • Table 35.45 Antibody Drug Conjugates: Distribution by Type of Payload
  • Table 35.46 Antibody Drug Conjugates: Distribution by Linker
  • Table 35.47 Antibody Drug Conjugates: Distribution by Type of Linker
  • Table 35.48 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2016-2023
  • Table 35.49 Clinical Trial Analysis: Distribution by Trial Status
  • Table 35.50 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
  • Table 35.51 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2016-2023
  • Table 35.52 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2016-2023
  • Table 35.53 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 35.54 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Table 35.55 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 35.56 Clinical Trial Analysis: Distribution by Target Population
  • Table 35.57 Clinical Trial Analysis: Distribution by Study Design
  • Table 35.58 Most Active Industry Players: Distribution by Number of Trials
  • Table 35.59 Most Active Non-Industry Players: Distribution by Number of Trials
  • Table 35.60 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
  • Table 35.61 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
  • Table 35.62 Global Demand for ADC Therapeutics, 2023-2035 (in kg)
  • Table 35.63 Global Demand for ADC Therapeutics: Distribution by Stage of Development, 2023-2035 (in kg)
  • Table 35.64 Global Commercial Demand for ADC Therapeutics, 2023-2035 (in kg)
  • Table 35.65 Global Commercial Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
  • Table 35.66 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2023-2035 (in kg)
  • Table 35.67 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
  • Table 35.68 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
  • Table 35.69 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
  • Table 35.70 Global Commercial Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
  • Table 35.71 Global Clinical Demand for ADC Therapeutics, 2023-2035 (in kg)
  • Table 35.72 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2023-2035 (in kg)
  • Table 35.73 Global Clinical Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
  • Table 35.74 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
  • Table 35.75 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
  • Table 35.76 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
  • Table 35.77 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
  • Table 35.78 Global Clinical Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
  • Table 35.79 Global ADC Contract Manufacturing Market, Historical Trends and Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.80 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Conservative Scenario (USD Billion)
  • Table 35.81 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Optimistic Scenario (USD Billion)
  • Table 35.82 Global ADC Contract Manufacturing Market: Distribution by Stage of Development, 2023, 2028 and 2035 (USD Billion)
  • Table 35.83 ADC Contract Manufacturing Market for Phase I ADCs, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.84 ADC Contract Manufacturing Market for Phase II ADCs, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.85 ADC Contract Manufacturing Market for Phase III ADCs, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.86 ADC Contract Manufacturing Market for Commercial ADCs, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.87 Global ADC Contract Manufacturing Market: Distribution by Process Component, 2023, 2028 and 2035 (USD Billion)
  • Table 35.88 ADC Contract Manufacturing Market for Antibody, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.89 ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payload, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.90 ADC Contract Manufacturing Market for Conjugation / Linker, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.91 ADC Contract Manufacturing Market for Fill / Finish, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.92 Global ADC Contract Manufacturing Market: Distribution by Target Indication, 2023, 2028 and 2035 (USD Billion)
  • Table 35.93 ADC Contract Manufacturing Market for Solid Tumors, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.94 ADC Contract Manufacturing Market for Hematological Tumors, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.95 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.96 Global ADC Contract Manufacturing Market: Distribution by Antibody Generation, 2023, 2028 and 2035 (USD Billion)
  • Table 35.97 ADC Contract Manufacturing Market for Second Generation, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.98 ADC Contract Manufacturing Market for Third Generation, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.99 ADC Contract Manufacturing Market for Fourth Generation, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.100 ADC Contract Manufacturing Market for Next Generation, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.101 Global ADC Contract Manufacturing Market: Distribution by Antibody Origin, 2023, 2028 and 2035 (USD Billion)
  • Table 35.102 ADC Contract Manufacturing Market for Human Origin, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.103 ADC Contract Manufacturing Market for Chimeric Origin, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.104 ADC Contract Manufacturing Market for Murine Origin, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.105 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.106 Global ADC Contract Manufacturing Market: Distribution by Antibody Isotype, 2023, 2028 and 2035 (USD Billion)
  • Table 35.107 ADC Contract Manufacturing Market for IgG1, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.108 ADC Contract Manufacturing Market for IgG4, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.109 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.110 Global ADC Contract Manufacturing Market: Distribution by Type of Payload, 2023, 2028 and 2035 (USD Billion)
  • Table 35.111 ADC Contract Manufacturing Market for Camptothecin, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.112 ADC Contract Manufacturing Market for Maytansinoid, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.113 ADC Contract Manufacturing Market for Auristatin, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.114 ADC Contract Manufacturing Market for DNA Topoisomerase I Inhibitor, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.115 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.116 Global ADC Contract Manufacturing Market: Distribution by Type of Linker, 2023, 2028 and 2035 (USD Billion)
  • Table 35.117 ADC Contract Manufacturing Market for Maleimide, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.118 ADC Contract Manufacturing Market for SMCC, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.119 ADC Contract Manufacturing Market for Tetrapeptide-based linker, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.120 ADC Contract Manufacturing Market for Valine-citrulline, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.121 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.122 Global ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Billion)
  • Table 35.123 ADC Contract Manufacturing Market in North America, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.124 ADC Contract Manufacturing Market in Europe, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.125 ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.126 Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.127 Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.128 Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.129 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Generation, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.130 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.131 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.132 Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.133 Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.134 Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.135 Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.136 Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.137 Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.138 Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.139 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.140 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.141 Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.142 Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Billion)
  • Table 35.143 Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Billion)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Forecast Methodology
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 2.4 Research Methodology: Key Market Segmentation
  • Figure 3.1 Lessons Learnt from Past Recessions
  • Figure 4.1 Executive Summary: Market Landscape
  • Figure 4.2 Executive Summary: Recent Expansions
  • Figure 4.3 Executive Summary: Partnerships and Collaborations
  • Figure 4.4 Executive Summary: Capacity Analysis
  • Figure 4.5 Executive Summary: Clinical Trial Analysis
  • Figure 4.6 Executive Summary: Demand Analysis
  • Figure 4.7 Executive Summary: Market Sizing and Opportunity Analysis
  • Figure 5.1 Key Components of an ADC
  • Figure 5.2 ADC Manufacturing Steps
  • Figure 5.3 Key Parameters while Selecting a CMO Partner
  • Figure 6.1 ADC Contract Manufacturers: Distribution by Year of Establishment
  • Figure 6.2 ADC Contract Manufacturers: Distribution by Company Size
  • Figure 6.3 ADC Contract Manufacturers: Distribution by Location of Headquarters (Region)
  • Figure 6.4 ADC Contract Manufacturers: Distribution by Location of Headquarters (Country)
  • Figure 6.5 ADC Contract Manufacturers: Distribution by Company Size and Location of Headquarters
  • Figure 6.6 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered
  • Figure 6.7 ADC Contract Manufacturers: Distribution by Location of Headquarters and ADC Manufacturing Service Offered
  • Figure 6.8 ADC Contract Manufacturers: Distribution by Type of Additional Service Offered
  • Figure 6.9 ADC Contract Manufacturers: Distribution by Scale of Operation
  • Figure 6.10 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered and Scale of Operation
  • Figure 6.11 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities and Type of ADC Manufacturing Service Offered
  • Figure 7.1 Lonza: Annual Revenues, FY 2019-H1 FY 2023 (CHF Billion)
  • Figure 7.2 WuXi Biologics: Annual Revenues, FY 2019-H1 FY 2023 (RMB Billion)
  • Figure 7.3 Catalent Pharma Solutions: Annual Revenues, FY 2019 - FY 2023 (USD Billion)
  • Figure 8.1 Company Competitiveness Analysis: ADC Contract Manufacturers based in North America
  • Figure 8.2 Company Competitiveness Analysis: ADC Contract Manufacturers based in Europe
  • Figure 8.3 Company Competitiveness Analysis: ADC Contract Manufacturers based in Asia-Pacific
  • Figure 8.4 Capability Benchmarking: Distribution of Top 9 Players (Wind Rose Representation)
  • Figure 9.1 Recent Expansions: Cumulative Year-wise Trend, 2013-2023
  • Figure 9.2 Recent Expansions: Distribution by Type of Expansion
  • Figure 9.3 Recent Expansions: Distribution by Purpose of Expansion
  • Figure 9.4 Recent Expansions: Distribution by Year of Expansion and Purpose of Expansion
  • Figure 9.5 Recent Expansions: Distribution by Scale of Operation
  • Figure 9.6 Recent Expansions: Distribution by Location of Expanded Facility
  • Figure 9.7 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
  • Figure 9.8 Most Active Players: Distribution by Number of Expansions
  • Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2012-2023
  • Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 10.4 Partnerships and Collaborations: Distribution by Purpose of Partnership
  • Figure 10.5 Partnerships and Collaborations: Distribution by Scale of Operation
  • Figure 10.6 Most Active Players: Distribution by Number of Partnership Instances
  • Figure 10.7 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
  • Figure 10.8 Partnerships and Collaborations: Distribution by Local and International Agreements
  • Figure 11.1 Make versus Buy Decision Making Framework
  • Figure 11.2 Make versus Buy Decision Making: Possible Scenario Descriptions
  • Figure 12.1 Value Chain Analysis: ADC Development Overview
  • Figure 12.2 Value Chain Analysis: ADC Contract Manufacturing Overview
  • Figure 12.3 ADC Therapeutics: Distribution by Cost of Raw Material Required for Clinical Stage Manufacturing
  • Figure 12.4 Value Chain Analysis: Distribution by Cost
  • Figure 12.5 Costs Associated with Antibody Manufacturing
  • Figure 12.6 Costs Associated with Payload and Linker Manufacturing
  • Figure 12.7 Costs Associated with Conjugation
  • Figure 12.8 Costs Associated with Fill / Finish
  • Figure 13.1 Global Installed ADC Manufacturing Capacity: Distribution by Company Size
  • Figure 13.2 Global Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
  • Figure 13.3 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Region)
  • Figure 13.4 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Country)
  • Figure 13.5 Global Installed ADC Manufacturing Capacity: Distribution by Key Players
  • Figure 14.1 Antibody Drug Conjugates: Distribution by Status of Development
  • Figure 14.2 Antibody Drug Conjugates: Distribution by Target Disease Indication
  • Figure 14.3 Antibody Drug Conjugates: Distribution by Therapeutic Area
  • Figure 14.4 Antibody Drug Conjugates: Distribution by Line of Treatment
  • Figure 14.5 Antibody Drug Conjugates: Distribution by Dosing Frequency
  • Figure 14.6 Antibody Drug Conjugates: Distribution by Type of Therapy
  • Figure 14.7 Antibody Drug Conjugates: Distribution by Target Antigen
  • Figure 14.8 Antibody Drug Conjugates: Distribution by Antibody Isotype
  • Figure 14.9 Antibody Drug Conjugates: Distribution by Payload / Cytotoxin / Warhead
  • Figure 14.10 Antibody Drug Conjugates: Distribution by Type of Payload
  • Figure 14.11 Antibody Drug Conjugates: Distribution by Linker
  • Figure 14.12 Antibody Drug Conjugates: Distribution by Type of Linker
  • Figure 15.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2016-2023
  • Figure 15.2 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 15.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
  • Figure 15.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2016-2023
  • Figure 15.5 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2016-2023
  • Figure 15.6 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 15.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Figure 15.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 15.9 Clinical Trial Analysis: Distribution by Target Population
  • Figure 15.10 Clinical Trial Analysis: Distribution by Study Design
  • Figure 15.11 Most Active Industry Players: Distribution by Number of Trials
  • Figure 15.12 Most Active Non-Industry Players: Distribution by Number of Trials
  • Figure 15.13 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
  • Figure 15.14 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
  • Figure 17.1 Global Demand for ADC Therapeutics, 2023-2035 (in kg)
  • Figure 17.2 Global Demand for ADC Therapeutics: Distribution by Stage of Development, 2023-2035 (in kg)
  • Figure 17.3 Global Commercial Demand for ADC Therapeutics, 2023-2035 (in kg)
  • Figure 17.4 Global Commercial Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
  • Figure 17.5 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2023-2035 (in kg)
  • Figure 17.6 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
  • Figure 17.7 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
  • Figure 17.8 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
  • Figure 17.9 Global Commercial Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
  • Figure 17.10 Global Clinical Demand for ADC Therapeutics, 2023-2035 (in kg)
  • Figure 17.11 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2023-2035 (in kg)
  • Figure 17.12 Global Clinical Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
  • Figure 17.13 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
  • Figure 17.14 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
  • Figure 17.15 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
  • Figure 17.16 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
  • Figure 17.17 Global Clinical Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
  • Figure 18.1 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in North America
  • Figure 18.2 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Europe
  • Figure 18.3 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World
  • Figure 19.1 AC Matrix: Pictorial Representation
  • Figure 19.2 AC Matrix: Overall ADC Contract Manufacturing Market Scenario, 2023-2028 and 2029-2035
  • Figure 19.3 AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
  • Figure 19.4 AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions
  • Figure 20.1 Global ADC Contract Manufacturing Market, Historical Trends and Forecasted Estimates, till 2035
  • Figure 20.2 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Base Scenario (USD Million)
  • Figure 20.3 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Conservative Scenario (USD Million)
  • Figure 20.4 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Optimistic Scenario (USD Million)
  • Figure 21.1 Global ADC Contract Manufacturing Market: Distribution by Stage of Development, 2023, 2028 and 2035 (USD Million)
  • Figure 21.2 ADC Contract Manufacturing Market for Phase I ADCs, Forecasted Estimates, till 2035 (USD Million)
  • Figure 21.3 ADC Contract Manufacturing Market for Phase II ADCs, Forecasted Estimates, till 2035 (USD Million)
  • Figure 21.4 ADC Contract Manufacturing Market for Phase III ADCs, Forecasted Estimates, till 2035 (USD Million)
  • Figure 21.5 ADC Contract Manufacturing Market for Commercial ADCs, Forecasted Estimates, till 2035 (USD Million)
  • Figure 22.1 Global ADC Contract Manufacturing Market: Distribution by Process Component, 2023, 2028 and 2035 (USD Million)
  • Figure 22.2 ADC Contract Manufacturing Market for Antibody, Forecasted Estimates, till 2035 (USD Million)
  • Figure 22.3 ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payload, Forecasted Estimates, till 2035 (USD Million)
  • Figure 22.4 ADC Contract Manufacturing Market for Conjugation / Linker, Forecasted Estimates, till 2035 (USD Million)
  • Figure 22.5 ADC Contract Manufacturing Market for Fill / Finish, Forecasted Estimates, till 2035 (USD Million)
  • Figure 23.1 Global ADC Contract Manufacturing Market: Distribution by Target Indication, 2023, 2028 and 2035 (USD Million)
  • Figure 23.2 ADC Contract Manufacturing Market for Solid Tumors, Forecasted Estimates, till 2035 (USD Million)
  • Figure 23.3 ADC Contract Manufacturing Market for Hematological Tumors, Forecasted Estimates, till 2035 (USD Million)
  • Figure 23.4 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
  • Figure 24.1 Global ADC Contract Manufacturing Market: Distribution by Antibody Generation, 2023, 2028 and 2035 (USD Million)
  • Figure 24.2 ADC Contract Manufacturing Market for Second Generation, Forecasted Estimates, till 2035 (USD Million)
  • Figure 24.3 ADC Contract Manufacturing Market for Third Generation, Forecasted Estimates, till 2035 (USD Million)
  • Figure 24.4 ADC Contract Manufacturing Market for Fourth Generation, Forecasted Estimates, till 2035 (USD Million)
  • Figure 24.5 ADC Contract Manufacturing Market for Next Generation, Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.1 Global ADC Contract Manufacturing Market: Distribution by Antibody Origin, 2023, 2028 and 2035 (USD Million)
  • Figure 25.2 ADC Contract Manufacturing Market for Humanized Origin, Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.3 ADC Contract Manufacturing Market for Chimeric Origin, Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.4 ADC Contract Manufacturing Market for Murine Origin, Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.5 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
  • Figure 26.1 Global ADC Contract Manufacturing Market: Distribution by Antibody Isotype, 2023, 2028 and 2035 (USD Million)
  • Figure 26.2 ADC Contract Manufacturing Market for IgG1, Forecasted Estimates, till 2035 (USD Million)
  • Figure 26.3 ADC Contract Manufacturing Market for IgG4, Forecasted Estimates, till 2035 (USD Million)
  • Figure 26.4 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
  • Figure 27.1 Global ADC Contract Manufacturing Market: Distribution by Type of Payload, 2023, 2028 and 2035 (USD Million)
  • Figure 27.2 ADC Contract Manufacturing Market for Camptothecin, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 27.3 ADC Contract Manufacturing Market for Maytansinoid, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 27.4 ADC Contract Manufacturing Market for Auristatin, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 27.5 ADC Contract Manufacturing Market for DNA Topoisomerase I Inhibitor, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 27.6 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
  • Figure 28.1 Global ADC Contract Manufacturing Market: Distribution by Type of Linker, 2023, 2028 and 2035 (USD Million)
  • Figure 28.2 ADC Contract Manufacturing Market for Maleimide, Forecasted Estimates, till 2035 (USD Million)
  • Figure 28.3 ADC Contract Manufacturing Market for SMCC, Forecasted Estimates, till 2035 (USD Million)
  • Figure 28.4 ADC Contract Manufacturing Market for Tetrapeptide-based linker, Forecasted Estimates, till 2035 (USD Million)
  • Figure 28.5 ADC Contract Manufacturing Market for Valine-citrulline, Forecasted Estimates, till 2035 (USD Million)
  • Figure 28.6 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
  • Figure 29.1 Global ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Million)
  • Figure 29.2 ADC Contract Manufacturing Market in North America, Forecasted Estimates, till 2035 (USD Million)
  • Figure 29.3 ADC Contract Manufacturing Market in Europe, Forecasted Estimates, till 2035 (USD Million)
  • Figure 29.4 ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World, Forecasted Estimates, till 2035 (USD Million)
  • Figure 30.1 Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
  • Figure 30.2 Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
  • Figure 30.3 Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
  • Figure 30.4 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Generation, Forecasted Estimates, till 2035 (USD Million)
  • Figure 30.5 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
  • Figure 30.6 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
  • Figure 30.7 Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
  • Figure 30.8 Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
  • Figure 30.9 Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.1 Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.2 Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.3 Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.4 Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.5 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.6 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.7 Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.8 Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.9 Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
  • Figure 33.1 Concluding Remarks: Market Landscape
  • Figure 33.2 Concluding Remarks: Recent Expansions
  • Figure 33.3 Concluding Remarks: Partnerships and Collaborations
  • Figure 33.4 Concluding Remarks: Clinical Trial Analysis
  • Figure 33.5 Concluding Remarks: Likely Partner Analysis
  • Figure 33.6 Concluding Remarks: Capacity Analysis
  • Figure 33.7 Concluding Remarks: Demand Analysis
  • Figure 33.8 Concluding Remarks: Market Sizing and Opportunity Analysis (1/3)
  • Figure 33.9 Concluding Remarks: Market Sizing and Opportunity Analysis (2/3)
  • Figure 33.10 Concluding Remarks: Market Sizing and Opportunity Analysis (3/3)